Top

Published in:

01-10-2020 | Sudden Cardiac Death | Original Article

Pharmacological spasm provocation testing in 2500 patients: provoked spasm incidence, complications and cardiac events

Author: Shozo Sueda

Published in: Heart and Vessels | Issue 10/2020

Abstract

Pharmacological spasm provocation tests such as acetylcholine (ACh) and ergonovine (ER) had been performed in the clinic. We retrospectively analyzed the incidence of provoked spasm, complications during testing and the cardiac events after these tests. From January 1991 and October 2018, we performed pharmacological spasm provocation tests in 2500 patients: 1810 ACh tests, 1232 ER tests, 542 both tests, and 310 ACh added after ER tests. ACh was injected in incremental doses of 20/50/100/200 μg into the LCA and 20/50/80 μg into the RCA. ER was administered as a total dose of 64 μg into the LCA and 40 μg into the RCA. When adding ACh after ER, the total dose was 50/80 μg into the RCA and 100/200 μg into the LCA. Positive spasm was defined as ≥ 90% stenosis and usual chest pain or ischemic ECG changes. Mean follow-up duration was 47.5 ± 29.9 months. Overall, provoked positive spasm was found in 1095 patients (43.8%). The incidence of positive provoked spasm during ACh testing was significantly higher than that during other tests (ACh: 48.7% vs. ER: 28.9%, Both: 24%, ACh added after ER: 33.5%, p < 0.001). Multiple spasms were remarkably more frequent during ACh testing compared with the other 3 types of testing (ACh: 28.2% vs. ER: 7.4%, Both: 4.1%, ACh added after ER: 13.2%, p < 0.001). No death or acute myocardial infarction was observed, while major complications during ACh testing were significantly more frequent than during ER testing. Readmission due to recurrent angina pectoris in spasm-positive patients was remarkably more frequent than in spasm-negative patients. The incidence of sudden cardiac death, ventricular fibrillation, and acute coronary syndrome were not different between the spasm-positive and spasm-negative groups during the follow-up periods. We could perform all spasm provocation tests without any irreversible complications. All sequential spasm provocation tests were useful for documenting coronary spasm.

Yasue H, Horio Y, Nakamura N, Fujii H, Imoto N, Sonoda R, Kugiyama K, Obata K, Morikami Y, Kimura T (1986) Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 74:955–963CrossRef

Okumura K, Yasue H, Matsuyama K, Goto K, Miyagi H, Ogawa H, Matsuyama K (1988) Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm. J Am Coll Cardiol 12:883–888CrossRef

Okumura K, Yasue H, Horio Y, Takaoka K, Matsuyama K, Kugiyama K, Fujii H, Morikami Y (1988) Multivessel coronary spasm in patients with variant angina: a study with intracoronary injection of acetylcholine. Circulation 77:535–542CrossRef

Sato K, Kaikita K, Nakayama N, Horio E, Yoshimura H, Ono T, Ohba K, Tsujita K, Kojima S, Tayama S, Hokimoto S, Matsui K, Sugiyama S, Yamabe H, Ogawa H (2013) Coronary vasomotor response to intracoronary acetylcholine injection, clinical features, and long-term prognosis in 873 consecutive patients with coronary spasm: analysis of a single-center study over 20 years. J Am Heart Assoc 2:e000227CrossRef

Ong P, Athabasiadis A, Borgulya G, Mahrholdt H, Kaski JC, Udo Secctem (2012) High prevalence of a pathological reponse to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries: The ACOVA study. J Am Coll Cardiol 59:655–662CrossRef

Zaya M, Mehta PK, Merz NB (2014) Provocative testing for coronary reactivity and spasm. J Am Coll Cardiol 63:103–109CrossRef

Salerno JA, Previtali M, Tavazzi L, Chimienti M, De Servi S, Medici A, Specchia G, Bobba P (1982) Multivessel coronary spasm as a cause of ischemic syncope in angina at rest. Eur Heart J 3:339–345CrossRef

Nakamura M, Takeshita A, Nose Y (1987) Clinical characteristics associated with myocardial infarction, arrhythmias, and sudden death in patients with vasospastic angina. Circulation 75:1110–1116CrossRef

Sueda S, Kohno H (2018) Impact of pharmacological spasm provocation test in patients with a history of syncope. Heart Vessels 33:126–133CrossRef

10.

Meisel SR, Mazur A, Chetboun I, Epshtein M, Canetti M, Gallimidi J, Katz A, Strasberg B, Peled B (2002) Usefulness of implantable cardioverter-defibrillator in refractory variant angina pectoris complicated by ventricular fibrillation in patients with angiographically normal coronary arteries. Am J Cardiol 89:1114–1116CrossRef

11.

Sueda S, Fukuda H, Watanabe K, Ochi N, Kawada H, Hayashi Y, Uraoka T (2001) Clinical characteristics and possible mechanism of paroxysmal atrial fibrillation induced by intracoronary injection of acetylcholine. Am J Cardiol 88:570–573CrossRef

12.

Sueda S, Kohno H, Fukuda H, Ochi N, Kawada H, Hayashi Y, Uraoka T (2004) Frequency of provoked coronary spasms in patients undergoing coronary arteriography using a spasm provocation test via intracoronary administration of ergonovine. Angiology 55:403–411CrossRef

13.

Sueda S, Saeki H, Otani T, Mineoi K, Kondou T, Yano K, Ochi T, Ochi N, Hayashi Y, Tsuruoka T, Kawada H, Matsuda S, Uraoka T (2000) Major complications during spasm provocation tests with an intracoronary injection of acetylcholine. Am J Cardiol 85:391–394CrossRef

14.

Sueda S, Kohno H, Ochi T, Uraoka T (2015) Overview of the acetylcholine spasm provocation test. Clin Cardiol 38:430–438CrossRef

15.

Sueda S, Kohno H, Ochi T, Uraoka T, Tsunemitus K (2017) Overview of the pharmacological spasm provocation test: comparisons between acetylcholine and ergonvoine. J Cardiol 69:57–65CrossRef

16.

Sueda S, Kohno H, Fukuda H, Ochi N, Kawada H, Hayashi Y, Uraoka T (2004) Clinical impact of selective spasm provocation tests: comparisons between acetylcholine and ergonovine in 1508 examinations. Coron Artery Dis 15:491–497CrossRef

17.

Scanlon PJ, Faxon DP, Audet AM, Leon DL, Carabello B, Murray JA, Dehmer GJ, Nissen SE, Eagle KA, Pepine CJ, Legako RD, Watson RM, Ritchie JL, Gibbons RJ, Chettlin MD, Russell RO, Eagle KA, Ryan TJ, Gardner TJ, Smith SC Jr, Garson AG Jr (1999) ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography). J Am Coll Cardiol 33:1756–1824CrossRef

18.

Pristipino C, Beltrame JF, Finocchiaro ML, Hattori R, Fujita M, Mongiardo R, Cianflone D, Sanna T, Sasayama S, Maseri A (2000) Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation 101:1102–1108CrossRef

19.

Beltrame JF, Sasayama S, Maseri A (1999) Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J Am Coll Cardiol 33:1442–1452CrossRef

20.

Hackett D, Larkin S, Chierchia S, Davies G, Kaski JC, Maseri A (1987) Induction of coronary artery spasm by a direct local action of ergonovine. Circulation 75:577–582CrossRef

21.

Bertrand ME, LaBlanche JM, Tilmant PY, Thieuleux FA, Delforge MR, Carre AG, Asseman P, Berzin B, Libersa C, Laurent JM (1982) Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. Circulation 65:1299–1306CrossRef

22.

Buxton A, Goldberg S, Hirshfeld JW, Wilson J, Mann T, Williams DO, Overlie P, Oliva P (1980) Refractory ergonovine induced coronary vasospasm: importance of intracoronary nitroglycerin. Am J Cardiol 46:329–334CrossRef

23.

Harding MB, Leithe ME, Mark DB, Nelson CL, Harrison JK, Hermiller JB, Davidson CJ, Pryor DB, Bashore TM (1992) Ergonovine maleate testing during cardiac catheterization: a 10-year perspective in 3447 patients without significant coronary artery disease or Prinzmetal’s variant angina. J Am Coll Cardiol 20:107–111CrossRef

24.

Sueda S, Kohno H (2016) Overview of complications during pharmacological spasm provocation tests. J Cardiol 68:1–6CrossRef

25.

Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A (2013) 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology [published correction appears in Eur Heart J 2014; 35: 2260–2261]. Eur Heart J 34:2949–3003CrossRef

26.

Anderson JI, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE II, Fesmire FM, Hochman JS, Levin TN, Lincoff M, Peterson ED, Theroux P, Wenger NK, Wright S (2013) 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2013; 127: e863–e864]. Circulation 127:e663–e828CrossRef

27.

Sueda S, Kohno H, Fukuda H, Ochi N, Kawada H, Hayashi Y, Uraoka T (2003) Induction of coronary artery response by two pharmacological agents: comparison between intracoronary injection of acetylcholine and ergonovine. Coron Artery Dis 14:451–457CrossRef

28.

Sueda S, Miyoshi T, Sasaki Y, Skaue T, Habara H, Kohno H (2015) Sequential spasm provocation tests might overcome a limitation of the standard spasm provocation tests. Coron Artery Dis 26:490–494CrossRef

29.

JCS joint working group (2014) Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary spastic angina). Circ J 78:2779–2801CrossRef

Title: Pharmacological spasm provocation testing in 2500 patients: provoked spasm incidence, complications and cardiac events
Author: Shozo Sueda
Publication date: 01-10-2020
Publisher: Springer Japan
Keywords: Sudden Cardiac Death
Acute Coronary Syndrome
Ventricular Fibrillation
Published in: Heart and Vessels / Issue 10/2020
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-020-01616-x

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pharmacological spasm provocation testing in 2500 patients: provoked spasm incidence, complications and cardiac events

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2020

On-site assessment of computed tomography-derived fractional flow reserve in comparison with myocardial perfusion imaging and invasive fractional flow reserve

Relationship between adenosine A2a receptor polymorphism rs5751876 and fractional flow reserve during percutaneous coronary intervention

The combination of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a novel predictor of intravenous immunoglobulin resistance in patients with Kawasaki disease: a multicenter study

The effects of serum iron level without anemia on long-term prognosis of patients with coronary heart disease complicated with chronic heart failure: a retrospective cohort study

Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia

Oscillating shear stress mediates mesenchymal transdifferentiation of EPCs by the Kir2.1 channel

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page